Tag Archives: intellectual property

Bayer v. Lupin – Patenting The Label Redux

In my post of January 13, 2011, I discussed AstraZeneca LP v. Apotex, a Fed. Cir. decision in which AZ argued successfully that the proposed  Apotex labeling for an anti-asthma drug would induce infringement if the generic were marketed with … Continue reading

Posted in Hatch-Waxman | Tagged , , , , , , , , , , , | Leave a comment

Supreme Court Declines To Review “New And Improved” Written Description Requirement

On Tuesday, the Supreme Court denied Centocor’s (now “Janssen”) petition for cert. and so let stand a ruling that Centocor’s patents on humanized monoclonal antibodies (covering Abbott’s Humira) are invalid for failure to meet the written description requirement (WDR) of … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , , , | Leave a comment

Griffith Hack And Ambercite Map The Alzheimer’s Disease Patent Landscape

Although I received this report: “Clearing The Fog; Patenting Trends For The Treatment Of Alzheimer’s Disease” both directly and from a number of colleagues, I won’t presume that it has been widely read, but it should be. (A copy of the … Continue reading

Posted in Miscellaneous | Tagged , , , , , | Leave a comment

A “Modest Proposal” For The RCE Crisis

Commentators, including Prof. Hal Wegner, have been sounding the alarm regarding the increasing number of requests for continuing examination that applicants are filing. The PTO projects 325,000 RCE’s by FY 2018. They have gone further in recent posts, in attributing … Continue reading

Posted in AIA Patent Reform, USPTO Practice and Policy | Tagged , , , , , , , , , , , | Leave a comment